Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01270399
  4. Details
NCT01270399 Clinical Trial

Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined. Clinical Trial

Official title:
Targeting ER-Golgi Homeostasis in an Advantageous Therapeutic Strategy in Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT01270399
Other study ID # MMC10160-2010CTIL
Secondary ID
Status Recruiting
Phase Phase 0
First received January 4, 2011
Last updated October 29, 2012
Start date January 2011
Est. completion date January 2013

Study information
Verified date March 2012
Source Meir Medical Center
Contact n/a
Is FDA regulated No
Health authority israel: CLALIT HEALTH SERVICE
Study type Observational

Clinical Trial Summary

Lung cancer remains the most common cause of cancer-related death in the world. The major advances in treatment of lung cancer have brought only minor improvements in survival therefore novel systemic treatment methods are urgently needed.

Protein levels are regulated by the protein homeostasis network that generates and protects the protein fold (ER and Golgi included).

The heat shock protein 90 (Hsp90) is an essential molecular chaperon involved in the posttranslational folding and stability of proteins. Hsp90 inhibition leads to accumulation of unfolded proteins and ER stress. The therapeutic efficacy of such inhibition may be augmented by co-administering it with other drugs that disrupt ER-Golgi homeostasis like histone deacetylase (HDAC) or proteasome inhibitors. ER-Golgi homeostasis disruption affects a wide network of proteins and pathways as such affords a systemic target. Thus, the investigators aimed to examine the effect of combined treatment of Hsp90 antagonist with proteasome or HDAC inhibitors on human lung cancer cell lines and primary cells.

Recruitment information / eligibility
Status Recruiting
Enrollment 20
Est. completion date January 2013
Est. primary completion date January 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- PATIENTS WITH PROVED DIAGNOSIS OF LUNG CARCINOMA THAT ARE CANDIDATS FOR RADICAL SURGICAL TREATMENT

Exclusion Criteria:

- PATIENTS WITH SUSPICION FOR LUNG CARCINOMA WITHOUT PATHOLOGYCAL DIAFNOSIS BEFORE SURGERY

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

  • Lung Neoplasms
  • The Combined Effect of Hsp90 Inhibitor and HDAC/Proteasome Inhibitors on Lung Cancer Cell Fate and ER-Golgi Homeostasis Will be Examined.

Locations
Country Name City State
Israel Meir Medical Center Kfar Saba

Sponsors (1)
Lead Sponsor Collaborator
Meir Medical Center

Country where clinical trial is conducted

Israel,